Biotech announced that the company recently received the “Drug Registration Certificate” for golimumab injections approved and issued by the State Drug Administration. The drug is the first golimumab biosimilar drug in China. The registered classification is Class 3.3 therapeutic biological product, with a specification of 50 mg/stick. The approved indications are rheumatoid arthritis and ankylosing spondylitis. The product has been approved for listing by NMPA, FDA, and EMA. The commercial licensing cooperation covers 118 countries and regions. The approved listing will help enhance the company's product market competitiveness, and may face the risk of market competition and sales uncertainty in the future.

Biotech announced that the company recently received the “Drug Registration Certificate” for golimumab injections approved and issued by the State Drug Administration. The drug is the first golimumab biosimilar drug in China. The registered classification is Class 3.3 therapeutic biological product, with a specification of 50 mg/stick. The approved indications are rheumatoid arthritis and ankylosing spondylitis. The product has been approved for listing by NMPA, FDA, and EMA. The commercial licensing cooperation covers 118 countries and regions. The approved listing will help enhance the company's product market competitiveness, and may face the risk of market competition and sales uncertainty in the future.